RTS,S and R21 in Africa’s Malaria Belt: Scientific Breakthrough, Real-World Impact, and Critical Debates on Equity and Implementation

1. Introduction: Malaria, Children, and the Search for a Vaccine

Malaria remains one of the world’s deadliest infectious diseases, despite being both preventable and treatable. The WHO World malaria report 2024 estimates 263 million malaria cases and 597,000 deaths in 2023, with 94% of cases and 95% of deaths occurring in the WHO African Region.Organisation mondiale de la santé+1 Children under five account for about three-quarters of all malaria deaths in Africa, meaning that nearly every minute, a young child dies from a disease for which we now have vaccines.Organisation mondiale de la santé+1

For decades, malaria vaccine development was considered extraordinarily difficult due to the complex life cycle of Plasmodium falciparum and its ability to evade immune responses. In 2021, however, the RTS,S/AS01 vaccine (Mosquirix) became the first malaria vaccine recommended by WHO for children living in moderate- to high-transmission settings.NITAG Resource Center+1 In 2023, WHO recommended a second vaccine, R21/Matrix-M, providing an additional tool and greatly expanding potential supply.Organisation mondiale de la santé+2PMC+2 WHO now summarizes both products in a dedicated Q&A on malaria vaccines, emphasizing that RTS,S and R21 are both safe and effective and expected to have major public-health impact when combined with other prevention measures.Organisation mondiale de la santé+1

Accessible overviews of malaria and the new vaccines are available in the WHO malaria fact sheet (who.int) and the CDC’s “Malaria Vaccines” page (cdc.gov/malaria). Organisation mondiale de la santé+1

2. Global Malaria Burden and the Role of Vaccines

2.1 Burden Concentrated in Africa

According to WHO and UNICEF, global malaria cases rose from 249 million in 2022 to around 263 million in 2023, with deaths remaining just under 600,000.Organisation mondiale de la santé+2Reuters+2 Approximately 76% of malaria deaths occur in children under five.UNICEF DATA+1 Just four countries—Nigeria, the Democratic Republic of Congo, Niger, and Tanzania—account for more than 50% of global malaria deaths, underscoring the highly concentrated nature of the burden.The Lancet+1

Despite important progress since 2000, global case numbers have plateaued and even risen over the last five years, with WHO and journalists pointing to climate change, conflict, population displacement, insecticide and drug resistance, and chronic under-funding as major obstacles.Reuters+1

2.2 Vaccines as a Complement to Existing Tools

Insecticide-treated bed nets, indoor residual spraying, seasonal malaria chemoprevention (SMC), and prompt effective treatment remain the foundation of malaria control. WHO, Gavi, and the Global Fund emphasize that vaccines will have the greatest impact when added to this existing toolkit rather than replacing it.theglobalfund.org+2CDC+2 When used together with SMC, RTS,S or R21 can prevent roughly 75% of malaria cases in young children in high-transmission areas.UNICEF+1

Gavi’s 2025 insight report “Rolling out vaccines to beat malaria together” notes that both RTS,S and R21 reduce clinical malaria cases by more than 50% in the year after the primary three-dose series, and that fourth (booster) doses or seasonal dosing can raise protection further.Gavi+1

3. RTS,S/AS01 (Mosquirix): First-Generation Malaria Vaccine

3.1 Design and Clinical Efficacy

RTS,S/AS01 is a pre-erythrocytic vaccine targeting the circumsporozoite (CS) protein of P. falciparum, fused to hepatitis B surface antigen and formulated with the AS01 adjuvant.NITAG Resource Center+1 Large phase-3 trials conducted in seven African countries between 2009 and 2014 showed that in children aged 5–17 months, RTS,S reduced clinical malaria by about 51% during the first year after vaccination (three primary doses + one booster), with meaningful reductions in severe malaria as well.Gavi+1

Long-term follow-up, however, indicates that efficacy wanes over time, especially in high-transmission settings. An Oxford University summary of a seven-year phase-2 trial reported that vaccine efficacy declined substantially, with faster decline in areas with intense transmission.Université d’Oxford+1

3.2 Real-World Effectiveness and Cost-Effectiveness

The WHO-coordinated Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya, and Malawi generated crucial “real-world” evidence. An interim analysis in The Lancet Global Health (2025) found that after one year of follow-up, RTS,S/AS01E introduction was associated with a 32% reduction in hospital admissions for severe malaria and a 9% reduction in overall hospital admissions among vaccinated children.The Lancet+2PubMed+2

Modeling studies commissioned by WHO show that RTS,S is cost-effective in high-burden settings, significantly reducing cases, severe disease, and deaths when delivered through routine immunization, particularly where transmission is perennial.Organisation Mondiale de la Santé+2Organisation Mondiale de la Santé+2

3.3 Scholarly Views and Critiques

Researchers generally agree that RTS,S represents a historic milestone but stress that it is a “modest-efficacy” vaccine that must be combined with other interventions. Laurens (2019) describes RTS,S as a “first-generation” tool with moderate efficacy yet substantial public-health potential.PMC

More critical voices point to:

• Waning immunity and potential “rebound”: Some analyses suggest that in very high-transmission areas, partial immunity plus waning protection may lead to a later rebound in cases, especially where only three doses are given or boosters are missed.PMC+1
• Operational complexity: The four-dose schedule (three doses starting at 5 months, plus a booster) is challenging for health systems already struggling with routine immunization and competing priorities.The Lancet+1
• Price and opportunity cost: Before recent price cuts, RTS,S was around US$10 per dose, raising questions about trade-offs versus nets, SMC, or other child-health interventions in constrained budgets.gsk.com+1

Nonetheless, most public-health scholars conclude that the net benefits are large, especially in high-burden African settings, provided that vaccination does not crowd out other proven interventions.PMC+1

4. R21/Matrix-M: Second-Generation Vaccine and New Debates

4.1 WHO Recommendation and Efficacy

In October 2023, WHO recommended R21/Matrix-M as the second malaria vaccine for children living in moderate- to high-transmission areas, following a positive review by SAGE and the Malaria Policy Advisory Group.Organisation mondiale de la santé+1 R21, developed by the University of Oxford and manufactured at scale by the Serum Institute of India, uses a similar antigenic target to RTS,S but different formulation and adjuvant.PMC+1

A multicentre phase-3 trial reported >75% efficacy against clinical malaria in children when R21 was given in a three-dose series before the rainy season, followed by annual boosters in areas with strongly seasonal transmission.The Lancet+1 UNICEF and WHO summarize both vaccines in a 2024 Q&A, concluding that RTS,S and R21 are safe, effective, and complementary tools.UNICEF+1

4.2 Supply, Pricing, and Programmatic Promise

WHO prequalified R21 in December 2023, opening the door to UN procurement.Organisation mondiale de la santé+1 Because the Serum Institute can produce large volumes at relatively low cost (under US$4 per dose, and now closer to US$3 after a 2025 Gavi–UNICEF price deal), R21 is expected to substantially ease global supply constraints.Reuters+1

Recent analyses in The Lancet and other journals argue that the combined deployment of R21 and RTS,S could help bend the curve of malaria cases if adequately funded and integrated into national strategies.PMC+1

4.3 Scholarly Questions and Cautions

Despite enthusiasm, several scholars urge caution:

• Follow-up duration: As Gavi notes, RTS,S has seven years of trial follow-up while R21 has shorter (≈12–24 month) efficacy data so far, making the long-term durability of R21 protection less certain.Gavi+1
• Comparability: Because both vaccines are now in use, “head-to-head” comparisons may be difficult; differences in deployment strategies and local epidemiology will complicate interpretation.PMC+1
• Implementation challenges: Perspective pieces highlight issues such as cold chain capacity, timely booster doses, and aligning vaccination with seasonal chemoprevention campaigns.PMC+1

An editorial in The Lancet (“R21/Matrix-M malaria vaccine: questions remain”) underscores that the vaccine is promising but must be monitored carefully for long-term safety, effectiveness, and equity in access.The Lancet+1

5. Critical Perspectives: Funding, Equity, and “Missed Potential”

Beyond clinical debates, a growing body of commentary focuses on political economy and ethics.

• Funding gaps and slow rollout. WHO estimates that around US$8.3 billion per year is needed for effective malaria control, but only about US$4 billion was available in 2023, constraining coverage of nets, SMC, and vaccines.Reuters+2The Guardian+2 Journalistic analyses in outlets such as Vox argue that Gavi’s current budget and cautious rollout strategy leave millions of vaccine doses unused, and that a more aggressive, fully funded expansion could save hundreds of thousands of additional lives.Vox+1
• Price and cost-effectiveness. Critics question whether higher-priced vaccines offer the best value compared to scaling up existing tools. However, updated cost-effectiveness modeling for RTS,S suggests that, at the new lower prices announced by GSK and Bharat Biotech (targeting <US$5 per dose by 2028), vaccination is highly cost-effective in high-burden African settings.gsk.com+2Organisation Mondiale de la Santé+2
• Equity and “vaccine apartheid.” Global health scholars also highlight the risk of reproducing inequities seen during COVID-19. Delays in financing, procurement, or delivery to rural African communities—despite the fact that 95% of malaria deaths occur in Africa—raise questions about global solidarity and justice.African Leaders Malaria Alliance+2The Guardian+2

Prof. Sir Brian Greenwood, a leading malaria expert, stresses in a 2025 interview that vaccines are “a game-changer but not a magic bullet,” and that success will depend on strong health systems, sustained funding, and integrating vaccines with other interventions rather than assuming they alone will eradicate malaria.Sabin Vaccine Institute+1

6. Key Data Tables

Table 1. Global Malaria Burden and the African Context

Table 2. Comparison of RTS,S/AS01 and R21/Matrix-M Malaria Vaccines

7. Conclusion: Promise, Complexity, and the Road Ahead

The arrival of RTS,S and R21 marks a historic turning point in the fight against malaria. For the first time, African children—who bear almost the entire burden of malaria deaths—can receive vaccines that meaningfully reduce their risk of infection, severe disease, and death. Clinical trials and real-world implementation studies show that these vaccines work, and that they are cost-effective when deployed alongside established tools such as insecticide-treated nets and seasonal chemoprevention.The Lancet+2PMC+2

At the same time, scholars, researchers, and policy critics remind us that vaccines are not a silver bullet. Concerns about waning immunity, possible rebound, logistical complexity, and chronic under-funding of malaria control remain very real.Vox+3PMC+3Université d’Oxford+3 The ethical and political questions are stark: Why are life-saving vaccines and basic tools still unavailable to so many children in rural Africa? What does a “just” malaria strategy look like in a world of constrained aid and growing climate shocks?

From an academic and policy perspective, the key priorities now include:

1. Strengthening routine immunization and community health systems to deliver multi-dose vaccine schedules reliably.
2. Ensuring predictable, long-term financing so that countries can scale vaccines without sacrificing other essential interventions.
3. Intensifying operational and social-science research on optimal delivery strategies, community acceptance, and equity.
4. Supporting African leadership in research and policymaking, so that the countries most affected by malaria shape the future of malaria vaccines and elimination strategies.

If these conditions are met, malaria vaccines could help transform what has long been a tragic inevitability—children dying from mosquito bites—into a preventable exception.

8. Suggested Further Readings and Web Resources

• WHO. (2024). Malaria Fact Sheet.
  Overview of global burden, prevention, treatment, and vaccines.
  https://www.who.int/news-room/fact-sheets/detail/malaria Organisation mondiale de la santé
• WHO. (2025). Q&A on Malaria Vaccines (RTS,S and R21).
  Detailed comparison of the two vaccines, recommended schedules, and safety.
  https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine Organisation mondiale de la santé
• Gavi. (2024). How effective are malaria vaccines?
  Accessible summary of RTS,S and R21 trial efficacy and seasonal strategies.
  https://www.gavi.org/vaccineswork/how-effective-are-malaria-vaccines Gavi
• Ndeketa, L., et al. (2025). Effectiveness of RTS,S/AS01E in real-world settings. The Lancet Global Health.
  Interim phase-4 analysis from Ghana, Kenya, and Malawi.
  (Open access via ResearchGate)
  https://www.researchgate.net/publication/397409110 The Lancet+1
• Datoo, M. S., et al. (2024). Safety and efficacy of R21/Matrix-M in African children. The Lancet.
  Pivotal phase-3 trial report for R21.
  https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02511-4/fulltext The Lancet
• PATH. (2024). Malaria Vaccines: RTS,S and R21 (Fact Sheet).
  Side-by-side comparison designed for policymakers.
  https://www.path.org/our-impact/resources/malaria-vaccines-rtss-and-r21/ Path
• GiveWell. (2024). Malaria Vaccines.
  In-depth charity evaluator perspective on effectiveness, uncertainties, and funding priorities.
  https://www.givewell.org/international/technical/programs/malaria-vaccines GiveWell

Quasi architebeatae vitae dicta sunt explicabo nemo enim ipsam volupatem quia voluptassit asper natur aut odit fugit sed quia consequuntur magni dolores eos qui ratione voluptam sequi nescunt neque porro quisquam  dolorem ipsum quia dolor sit amet consectetur adipiscing velit sed quia numquam eius moditempora incidunt ut labore et dolore consectetur adipisicing elit sed eius mod tempor incididunt.labore et dolore magna aliqua enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi aliquip ex ea commodo consequat. duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium totam rem aperiam.